Determination of thiopurine methyltransferase genotype in the patients with inflammatory bowel disease before and during azathioprine therapy

Archives of Gastroenterohepatology

Volumn 22, Issue 1-2, 2003, Pages 5-9

  Jojić, Njegica ^a   Urošević, Jelena ^b   Bojić, Božidar ^a   Pavlović, Sonja ^b  

^a Zvezdara University Clinical Center   (Serbia)

^b Institute of Molecular Genetics and Genetic Engineering   (Serbia)

Author keywords

Azathioprine; Inflammatory bowel disease; Leukopenia; Thiopurine S methyltransferase

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; PANCYTOPENIA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ULCERATIVE COLITIS; WILD TYPE;

EID: 0042530492     PISSN: 03542440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sanborn WJ. Azathioprine: State of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-9.
2. Cuffari C. Azathioprine metabolism in inflammatory bowel disease. Proceedings of the Falk Symposium 111, Frieburg 2000; 226-235.
3. Colombel JF, Ferrari N, Debuysere H, Marteau P, gendre JP, Bonaz B, Soule JC, Modigliani r, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S- methyltransverase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118(6): 1025-30.
4. Regueiro M, Mardini H. determination of Thiopurine Methyltransverase Genotype or Phenotype Optimizes Initial Dosing of Azathioprine for the Treatment of Crohn's Disease.
5. Sanborn W, Sutherland L, Person D, et al. Azathioprine os 6-mercaptopurine for inducing remission of Crohn's disease. The Cochrane Database of Systematic Reviews Issue 2, 2002.
6. Yates CR, Krynetski EY, Loennechen T, fessing MY, Tai HL, Pin CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransverase deficiency:genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern med 1997; 126; 608-614.
7. Tai Hl, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE. Thiopurine S - methyltransverase deficiency: two nucleotid transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702.
8. Otternes D, Szumlanski C, Lennard L, Klemetsdal B, arbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R. Human thiopurine methyltransverase pharmacogenetics: gene sequence polymorphism. Clin Pharmacol ther 1997;62:60-73.
9. Spire Vayron de la Moureyre C, Dehuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo RM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F. Genotypic and phenotypic analysis of the thiopurine S-methyltransverase gene (TPMT) in a European population. Br J Pharmacol 1998; 125;879-887.
10. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, deflander J, Greapler F, Schmiegelov K, Gregor M, Zanger UM, Eichelbaum M, Schwab M. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-142.
11. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990;336:225-229.
12. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Weiben E, Weinshilboum RM. Thiopurine methyl-transverase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
13. Szulmanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransverase: possible mechanism for interaction with 6 - mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
14. Lewis LD, Benin A, Szumlanski CL at al. Olsalazine and 6-mercaptopurine related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
15. Smith JA. Neutropenia associated with metronidazole therapy (latter). CMAJ 1980;123-202.
16. Feusner JH, Slicher SJ, Harker LA. Mechanisms of tromobocytopenia in varicella. Am J Hematol 1979;7:255-264.
17. Veraldi S, Rizziteli G, Lunghi G, Gardone R. Primary infection by human parvovirus B19. Dermatology 1993;186:72-74.
18. Seidman EG. Clinical use and practical application of TPMT enzyme an mercaptopurine metabolite monitoring in IBC. Rev. Gastroenterol Disord 2003;3 Supll 1:S30-8